Sutro Biopharma Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Sutro Biopharma Inc 's ROA in the second quarter of 2026?
Sutro Biopharma Inc recorded a cumulative net loss of $-181 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -88.14%.

However, within the Healthcare sector 711 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4116, from total ROA ranking in the first quarter of 2026 at 4869.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-25.88 %	-24.72 %	-55.11 %	-53.64 %	-46.35 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-181	-154	-191	-217	-209
Return On Assets (TTM)	-88.14 %	-69.22 %	-79.04 %	-73.45 %	-58.67 %
STRO's Total Ranking	# 4116	# 4869	# 4226	# 4170	# 4264
Total Assets (TTM) in million	194	242	174	209	262
Seq. Total Assets Change	-19.64 %	39.21 %	-17.01 %	-20.16 %	-18.38 %
Seq. Net Income Change	-	-	-	-	-

STRO's 5 Years Annual ROA >> Back to STRO Management Effectiveness >> Compare STRO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 110
Sector	# 712
Overall	# 4174

Return On Assets Statistics
High	Average	Low
5.64 %	-36.07 %	-88.12 %
(Sep 30 2020)		(Jun 30 2026)

Financial Statements
Sutro Biopharma Inc 's Assets	$ 194 million	STRO's Balance sheet
Sutro Biopharma Inc 's Income	$ -39 million	Quarterly STRO's Income Statement
STRO's Income by Division		See STRO's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-55.11 %	-17.74 %	15.72 %	19.15 %	-13.37 %
Total Assets in million	174	387	471	407	341
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-191	-227	-107	-119	-106
Annual Return On Assets	-109.93 %	-58.74 %	-22.69 %	-29.3 %	-30.91 %

STRO's 5 Years Annual ROA >> Back to STRO Management Effectiveness >> Compare STRO ROA to its Competitors

More Return On Assets Ratios
STRO's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
STRO's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for STRO's Competitors
Subscribers only: Roa for Sutro Biopharma Inc 's Suppliers
Subscribers only: Return On Assets for STRO's Customers

You may also want to know
STRO's Roi	STRO's Inventory Turnover Ratio	STRO's Growth Rates	STRO's Dividend Comparisons
	STRO's Profitability Ratios	STRO's Asset Turnover Ratio	STRO's Dividend Growth
STRO's Roe	STRO's Valuation Ratios	STRO's Financial Strength Ratios	STRO's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-03T12:17:35+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.